Because you can buy the early stage gems for a nominal initial outlay. Kazia can't afford to pay 50 million upfront for a drug.
As for the CR's...name me 1 small cap biotech that doesn't sell stock to raise funds?
How else will they fund the trials? I think you're being a bit tough on management.
Ann: Kazia Corporate Presentation, page-29
-
- There are more pages in this discussion • 38 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)